The study details the discovery of a species of Burkholderia gladioli isolated from the saliva and mucus of a pediatric cystic fibrosis patient. The bacterium produces an antibiotic called gladiolin, which was found to be active against multiple isolates of drug-resistant strains of TB in the laboratory setting.
“Overall, these data suggest that gladiolin may represent a useful starting point for the development of novel drugs to tackle multidrug-resistant TB,” wrote the study’s authors.
To learn more about drug-resistant TB, click here.
More articles on infection control:
Chronic Lyme disease treatments put patients at risk for serious harm, says CDC
The Joint Commission releases compendium of VTE care resources
CRE endemic across DC healthcare facilities, study suggests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
